Quality of life in systemic lupus erythematosus: Description in a cohort of French patients and association with blood hydroxychloroquine levels

Lupus

Volumn 25, Issue 7, 2016, Pages 735-740

  Jolly, M ^a   Galicier, L ^b   Aumaitre O ^c   Frances C ^d   Le Guern, V ^b   Liote F ^b   Smail, A ^e   Limal, N ^f   Perard, L ^g   Desmurs Clavel, H ^g   Boutin, D L T H ^d   Asli, B ^b   Kahn, J E ^h   Pourrat, J ⁱ   Sailler, L ⁱ   Ackermann, F ^h   Papo, T ^b   Sacre K ^b   Fain, O ^j   Stirnemann, J ^k   Cacoub, P ^l   Jallouli, M ^b   Leroux, G ^d   Cohen Bittan, J ^d   Hulot, J S ^d   Arora, S ^a   Amoura, Z ^d   Piette, J C ^d   Costedoat Chalumeau, N ^b   more..

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c UNIVERSITÉ CLERMONT AUVERGNE   (France)

^d SORBONNE UNIVERSITÉ   (France)

^e AMIENS UNIVERSITY HOSPITAL   (France)

^f HENRI MONDOR HOSPITAL   (France)

^g EDOUARD HERRIOT HOSPITAL   (France)

^h FOCH HOSPITAL   (France)

ⁱ UNIVERSITÉ PAUL SABATIER   (France)

^j HÔPITAL SAINT ANTOINE   (France)

^k GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^l ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

more..

Author keywords

blood concentration; Hydroxychloroquine; patient reported outcomes; quality of life; systemic lupus erythematosus

Indexed keywords

HYDROXYCHLOROQUINE; PLACEBO; PREDNISONE; ANTIRHEUMATIC AGENT;

ADULT; AFRICAN; ARTICLE; ASIAN; BLOOD LEVEL; CAUCASIAN; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; DOUBLE BLIND PROCEDURE; FEMALE; FRENCHMAN; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SHORT FORM 36; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; BLOOD; CLINICAL TRIAL; FRANCE; MIDDLE AGED; STATISTICAL MODEL;

ADULT; ANTIRHEUMATIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; FRANCE; HUMANS; HYDROXYCHLOROQUINE; LINEAR MODELS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; QUALITY OF LIFE;

EID: 84966668408     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203315627200     Document Type: Article

References (26)

1. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA,. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010; 69: 20-28.
2. Alarcon GS, McGwin G Jr, Bertoli AM, et al. Effect of hydroxychloroquine in the survival of patients with systemic lupus erythematosus. data from lumina, a multiethnic us cohort (LUMINA L). Ann Rheum Dis 2007; 66: 1168-1172.
3. Shinjo SK, Bonfa E, Wojdyla D, et al. Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort. Arthritis Rheum 2010; 62: 855-862.
4. Munster T, Gibbs JP, Shen D, et al. Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. Arthritis Rheum 2002; 46: 1460-1469.
5. Tett SE, Cutler DJ, Beck C, Day RO,. Concentration-effect relationship of hydroxychloroquine in patients with rheumatoid arthritis: a prospective, dose ranging study. J Rheumatol 2000; 27: 1656-1660.
6. Frances C, Cosnes A, Duhaut P, et al. Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study. Arch Dermatol 2012; 148: 479-484.
7. Costedoat-Chalumeau N, Amoura Z, Hulot JS, et al. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum 2006; 54: 3284-3290.
8. Costedoat-Chalumeau N, Galicier L, Aumaitre O, et al. Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS study). Ann Rheum Dis 2013; 72: 1786-1792.
9. Costedoat-Chalumeau N, Amoura Z, Hulot JS, et al. Very low blood hydroxychloroquine concentrations as an objective marker of poor adherence to treatment in systemic lupus erythematosus. Ann Rheum Dis 2007; 66: 821-824.
10. Costedoat-Chalumeau N, Le Guern V, Piette JC,. Determining adherence to therapeutic regimens in patients with chronic illness: comment on the article by Waimann et al. Arthritis Rheumatol 2014; 66: 770-770.
11. Costedoat-Chalumeau N, Pouchot J, Guettrot-Imbert G, et al. Adherence to treatment in systemic lupus erythematosus patients. Best Pract Res Clin Rheumatol 2013; 27: 329-340.
12. Alexander S, Chusney G, Chusney VD, Lee J, Cairns T, Lightstone L,. The achilles heel of lupus nephritis treatment: identifying non adherence using hydroxychloroquine blood levels. J Am Soc Nephrol 2013; abstract.
13. Ting TV, Kudalkar D, Nelson S, et al. Usefulness of cellular text messaging for improving adherence among adolescents and young adults with systemic lupus erythematosus. J Rheumatol 2012; 39: 174-179.
14. Durcan L, Clarke WA, Magder LS, Petri M. Hydroxychloroquine blood levels in systemic lupus erythematosus: Clarifying dosing controversies and improving adherence. J Rheumatol 2015; 42(11): 2092-7. doi: 10.3899/jrheum.150379. Epub 1 October 2015.
15. Lee JY, Luc S, Greenblatt DJ, Kalish R, McAlindon TE,. Factors associated with blood hydroxychloroquine level in lupus patients: renal function could be important. Lupus 2013; 22: 541-542.
16. Strand V, Gladman D, Isenberg D, Petri M, Smolen J, Tugwell P,. Endpoints: consensus recommendations from OMERACT IV. Outcome measures in rheumatology. Lupus 2000; 9: 322-327.
17. Jolly M, Utset TO,. Can disease specific measures for systemic lupus erythematosus predict patients health related quality of life? Lupus 2004; 13: 924-926.
18. McElhone K, Abbott J, Shelmerdine J, et al. Development and validation of a disease-specific health-related quality of life measure, the LupusQol, for adults with systemic lupus erythematosus. Arthritis Rheum 2007; 57: 972-979.
19. Gallop K, Nixon A, Swinburn P, Sterling KL, Naegeli AN, Silk ME,. Development of a conceptual model of health-related quality of life for systemic lupus erythematosus from the patient's perspective. Lupus 2012; 21: 934-943.
20. Dua AB, Touma Z, Toloza S, Jolly M,. Top 10 recent developments in health-related quality of life in patients with systemic lupus erythematosus. Curr Rheumatol Rep 2013; 15: 380-380.
21. Hochberg MC,. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725-1725.
22. Petri M, Kim MY, Kalunian KC, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005; 353: 2550-2558.
23. McHorney CA, Ware JE Jr, Raczek AE,. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993; 31: 247-263.
24. Aggarwal R, Wilke CT, Pickard AS, et al. Psychometric properties of the EuroQol-5D and Short Form-6D in patients with systemic lupus erythematosus. J Rheumatol 2009; 36: 1209-1216.
25. Kuriya B, Gladman DD, Ibanez D, Urowitz MB,. Quality of life over time in patients with systemic lupus erythematosus. Arthritis Rheum 2008; 59: 181-185.
26. Strand V, Levy RA, Cervera R, et al. Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials. Ann Rheum Dis 2014; 73: 838-844.